From our Center
Articles, News, Press Releases
Winter 2020 / Spring 2021
Alison Marsden, PhD and Melody Dong, PhD
Helping children with cardiovascular defects
Dr. Alison Marsden, Associate Professor of Pediatrics and Bioengineering and Vera Moulton Wall Center Faculty, and Stanford Bio-X Fellow Melody Dong, discuss how Bio-X has supported their research using fluid dynamics simulations to study blood flow in pulmonary arterial hypertension due to congenital heart defects. They hope that this work will lead to new treatments for children with pulmonary hypertension.
Rachel K. Hopper, MD
Dr. Rachel Hopper impacts the lives of children through CRIB Program
Wall Center faculty Rachel K. Hopper, MD, Clinical Assistant Professor in the Division of Pediatric Cardiology and co-director of CRIB (Cardiac and Respiratory Care for Infants with BPD) Program, was recently featured in two patient stories highlighting the benefits of sub-specialty collaborations and multidisciplinary team approaches, for infants born prematurely with Bronchopulmonary dysplasia (BPD) and pulmonary hypertension (PH), or PH risk factors.
Read the articles:
Vinicio de Jesus Perez, MD
Congratulations Dr. Vinicio de Jesus Perez!
Congratulations to Wall Center Facuty Vinicio de Jesus Perez, MD, Associate Professor of Medicine in Pulmonary, Allergy, and Critical Care Medicine who has been named as the first Stanford Pulmonary, Allergy and Critical Care Director of Faculty and Fellow Diversity and Inclusion. In this role, Dr. de Jesus Perez "will work with Department of Medicine leadership on initiatives that will continue to promote diversity and equality for fellows and faculty. We learned in 2020 that our ICUs, hospital wards, and clinics are a stage upon which societal ills meet medical care; our discipline is on the frontline of this challenging interface".
Roham Zamanian, MD, FCCP
Special Edition phaware® Podcast with Dr. Roham Zamanian
Our friends at phaware® shared a special edition podcast with Roham Zamanian, MD, FCCP, Associate Professor in the Division of Pulmonary, Allergy and Critical Care Medicine and Director of the Adult Pulmonary Hypertension Program, discussing the coronavirus (COVID-19) and gives specific advice for the PH Community.
Vinicio de Jesus Perez, MD and Roham Zamanian, MD, FCCP
Congratulations to Vinicio de Jesus Perez and Roham Zamanian for a High Impact COVID-19 Story
Roham Zamanian, MD, FCCP, Associate Professor in the Division of Pulmonary, Allergy and Critical Care Medicine and Director of the Adult Pulmonary Hypertension Program and Vinicio de Jesus Perez, MD, Associate Professor of Medicine in Pulmonary, Allergy, and Critical Care Medicine, along with other distinguished colleagues, published their fascinating case report in the American Journal of Respiratory and Critical Care Medicine detailing the outpatient management of a patient with concomitant idiopathic pulmonary arterial hypertension (iPAH) and COVID-19 disease using inhaled nitric oxide (iNO).
Kristina Kudelko, MD
Roham Zamanian, MD, FCCP
Roham Zamanian, MD, FCCP, Associate Professor in the Division of Pulmonary, Allergy and Critical Care Medicine and Director of the Adult Pulmonary Hypertension Program, along with leading pulmonary hypertension clinicians published an express manuscript about caring for PH patients with COVID-19.
Abstract: The COVID-19 pandemic presents many unique challenges when caring for patients with pulmonary hypertension (PH).The COVID-19 pandemic has altered routine standard of care practice and the acute management particularly for those patients with pulmonary arterial hypertension (PAH), where PAH-specific treatments are used. It is important to balance the ongoing care andevaluation of PAH patients with “exposure risk” to COVID-19 for patients coming to clinic or the hospital. If there is a morbidity and mortality benefit from starting PAH therapies, for example in a patient with high-likelihood of PAH, then it remains important to complete the thorough evaluation. However, the COVID-19 outbreak may also represent a unique time when PH experts have to weigh the risks and benefits of the diagnostic work-up including potential exposure to COVID-19 versus initiatingtargeted PAH therapy in a select high-risk, highlikelihood World Symposium Pulmonary Hypertension (WSPH) Group 1 PAH patients.This document will highlight some of the issues facing providers, patients and the PAH community in real-time as the COVID-19 pandemic isevolving and is intended to share expected common clinical scenarios and best clinical practices to help the community at-large.